Buzzy gene-editing startup Tome Biosciences is floundering, just nine months after launching with $213 million in funding, according to several sources with direct knowledge of the matter.
One person with knowledge of the situation told STAT that Tome is winding down operations altogether and seeking a buyer by Nov. 1. Another source reported that there are still options on the table to keep the biotech running. Both spoke on condition of anonymity to be able to speak candidly.
In a statement, a spokesperson for Tome said that the company had seen “clear scientific progress” but that “investor sentiment has shifted dramatically across the gene editing space, particularly for preclinical companies.”
“Given this, the company is operating at reduced capacity, maintaining core expertise, and we are in ongoing confidential conversations with multiple parties to explore strategic options,” the spokesperson said.
